Cybin Inc. (OTCMKTS:CYBN – Get Free Report) was up 0.5% during trading on Monday . The stock traded as high as $7.33 and last traded at $7.33. Approximately 220,908 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 294,872 shares. The stock had previously closed at $7.29.
Cybin Price Performance
The firm’s 50 day moving average is $9.07 and its 200 day moving average is $8.47. The company has a market capitalization of $157.64 million, a PE ratio of -38.63 and a beta of 0.50.
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Stories
- Five stocks we like better than Cybin
- Why Are Stock Sectors Important to Successful Investing?
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Consumer Staples Stocks, Explained
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- The Most Important Warren Buffett Stock for Investors: His Own
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.jpg?v=20230301141913&h=45&w=95&zc=2){kind=logo}